Posted by Michael Wonder on 04 Apr 2023
FDA accepts Pfizer’s supplemental new drug applications for Braftovi + Mektovi
4 April 2023 - Supplemental new drug applications are supported by results from the PHAROS trial, evaluating the combination in BRAF V600E mutant metastatic non-small-cell lung cancer.
Pfizer announced today that the US FDA has accepted for review the supplemental new drug applications for Braftovi (encorafenib) + Mektovi (binimetinib) for patients with metastatic non-small-cell lung cancer with a BRAF V600E mutation, as detected by an FDA approved test.
